Assembly Biosciences, Inc.

13.00 USD
-0.47 (-3.49%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Assembly Biosciences, Inc. stock is up 9.43% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35.71% of the previous 13 March’s closed higher than February.

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc. discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.